Cortexyme Inc (NQ: CRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.890 (7)
Ask (Size) 1.990 (2)
Prev. Close 1.950
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 36,382,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
Via Benzinga

Performance

More News

Read More
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
From Cortexyme, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cortexyme Appoints June Bray to its Board of Directors
From Cortexyme, Inc.
Via Business Wire
69 Biggest Movers From Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Acquisition of Novosteo
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
From Cortexyme, Inc.
Via Business Wire
103 Biggest Movers From Yesterday
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Cortexyme Announces Agreement to Acquire Novosteo
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
Via SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
From Cortexyme, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.